Liver Cirrhosis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Liver Cirrhosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Liver Cirrhosis - Pipeline Review, H2 2016', provides an overview of the Liver Cirrhosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
- The report reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Liver Cirrhosis therapeutics and enlists all their major and minor projects
- The report assesses Liver Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Liver Cirrhosis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Liver Cirrhosis Overview 8
Therapeutics Development 9
Pipeline Products for Liver Cirrhosis - Overview 9
Pipeline Products for Liver Cirrhosis - Comparative Analysis 10
Liver Cirrhosis - Therapeutics under Development by Companies 11
Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes 12
Liver Cirrhosis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Liver Cirrhosis - Products under Development by Companies 16
Liver Cirrhosis - Products under Investigation by Universities/Institutes 17
Liver Cirrhosis - Companies Involved in Therapeutics Development 18
Conatus Pharmaceuticals Inc. 18
Digna Biotech, S.L. 19
Galectin Therapeutics, Inc. 20
Human Stem Cells Institute 21
Nimbus Therapeutics, LLC 22
Ocera Therapeutics, Inc. 23
Pharmicell Co., Ltd. 24
S-Evans Biosciences, Inc. 25
Stelic Institute & Co., Inc. 26
Liver Cirrhosis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Cellgram-LC - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
DB-027 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DB-036 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
emricasan - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Gemacell - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
GRMD-02 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
GXHPC-1 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
ND-654 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
ornithine phenylacetate - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis and Pneumoconiosis - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Stem Cell Therapy for Liver Cirrhosis and Rheumatoid Arthritis - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
STNM-04 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Liver Cirrhosis - Dormant Projects 71
Liver Cirrhosis - Discontinued Products 72
Liver Cirrhosis - Product Development Milestones 73
Featured News & Press Releases 73
May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial 73
Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data 74
Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting 75
Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial 76
Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting 77
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 78
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 78
Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting 79
Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement 79
May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam 81
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 82
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 83
Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 83
Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables

Number of Products under Development for Liver Cirrhosis, H2 2016 9
Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc., H2 2016 18
Liver Cirrhosis - Pipeline by Digna Biotech, S.L., H2 2016 19
Liver Cirrhosis - Pipeline by Galectin Therapeutics, Inc., H2 2016 20
Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H2 2016 21
Liver Cirrhosis - Pipeline by Nimbus Therapeutics, LLC, H2 2016 22
Liver Cirrhosis - Pipeline by Ocera Therapeutics, Inc., H2 2016 23
Liver Cirrhosis - Pipeline by Pharmicell Co., Ltd., H2 2016 24
Liver Cirrhosis - Pipeline by S-Evans Biosciences, Inc., H2 2016 25
Liver Cirrhosis - Pipeline by Stelic Institute & Co., Inc., H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Liver Cirrhosis - Dormant Projects, H2 2016 71
Liver Cirrhosis - Discontinued Products, H2 2016 72